On the one hand, unlike other subtypes of breast cancer, HR+/HER2+ breast cancer is endowed with distinct molecular biological characteristics, therapeutic responses and drug resistance mechanisms due to the complex interaction between HR and the HER2 signaling pathway.5, 6. This evidence concerns the gene ERBB2 and breast carcinoma.